focus -WSS

focus

author：Wikipedia 2025-09-27 18:30:06 - browse：317

The Food and Drug Administration is poised to tell drug and medical device makers how to better include people of color in the clinical trials that test whether products work and are safe, an agency official said Wednesday. Those guidelines are five months late.

To ensure that drugs work for everyone, they must be tested on a representative sample of people. But researchers have found that many clinical trials exclude the people of color who are often most affected by the diseases that drugs treat.

To help fix that problem, Congress passed a law requiring companies to give the FDA their plans for diversifying clinical trials. As part of that process, the agency was expected to issue guidance by the end of last year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： VC firm General Catalyst wants to buy a health system

WSS

Physician executives need more than on

Was Amgen transparent enough on FDA's concern on cancer drug?

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Coercive sterilizations revealed by STAT prompt outrage

Medical device trials still don't enroll enough women, study finds

FDA panel signals lack of confidence in Amgen cancer drug data

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

Medical records are filled with copy

California wildfire smoke linked to 52,000 early deaths, study says

How one medical school became remarkably diverse

AI can decode, harness the power of the humane immune system

Medicare proposal to cover medical devices draws a mixed reaction

'Essentially witchcraft:' A former naturopath takes on the field

Medical records are filled with copy

Cheap, fast test for Zika and dengue could cost just $1

In age of alternative facts, a scholarly course on calling out crap

Bristol 'take

focus

Teladoc has a new CEO, but challenges remain the same

Why age limits for politicians are a terrible idea

Pharma companies must ensure equitable access to obesity drugs

The future of health care in the House

California wildfire smoke linked to 52,000 early deaths, study says

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Wikipedia

Wikipedia

Wikipedia

knowledge